Brief: Valbiotis Announces It Has Submitted To Authorities Three Clinical Protocols For TOTUM•854

Valbiotis SA

01/12/2021 06:52

Dec 1 (Reuters) - Valbiotis SA  ALVAL.PA :
    * VALBIOTIS ANNOUNCES THAT IT HAS SUBMITTED TO THE COMPETENT
AUTHORITIES THE THREE CLINICAL PROTOCOLS FOR TOTUM•854 INDICATED
IN THE REDUCTION OF BLOOD PRESSURE AND PRESENTS ITS
COMPREHENSIVE CLINICAL DEVELOPMENT PLAN
    * RESULTS ARE EXPECTED AT END OF 2022
    * CLINICAL STUDY OF THE BIOAVAILABILITY AND MODE OF ACTION
OF
TOTUM•854, TO CHARACTERIZE ITS METABOLITES AND IDENTIFY THEIR
EFFECTS ON HUMAN CELL LINES, WILL BE CONDUCTED IN FRANCE ON 10
VOLUNTEERS
    * INSIGHT INTERNATIONAL, MULTICENTER, RANDOMIZED,
PLACEBO-CONTROLLED PIVOTAL PHASE II/III CLINICAL STUDY WILL BE
CONDUCTED WITH A 3.7 G/DAY DOSE OF TOTUM•854 ON 400 VOLUNTEERS
    * A SIGNIFICANT ACUTE EFFECT WAS ALSO OBSERVED FOLLOWING A
SINGLE
DOSE OF TOTUM•854 ON SAME EARNINGS PER SHARE MODEL
    * END OF RECRUITMENT IS EXPECTED AT FIRST SEMESTER OF 2023

Source text for Eikon:  ID:nBwjLdzha 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))